First topical PDE4 inhibitor approved for plaque psoriasis
ADC评论
August 2, 2022
Recently, Arcutis Biotherapeutics announced that the FDA approved the topical selective PDE4 inhibitor ZORYVE (Roflumilast, roflumilast) cream 0.3% for the treatment of plaque psoriasis in
